New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
12:01 EDTGILD, BTUStocks with call strike movement; BTU GILD
Peabody (BTU) September 22 call option implied volatility increased 4% to 34, Gilead (GILD) August 90 option implied volatility decreased 2% to 30 according to IVolatility.
News For BTU;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 28, 2015
13:39 EDTGILDGilead technical notes before results
Subscribe for More Information
11:42 EDTGILDStocks with call strike movement; FB GILD
Subscribe for More Information
08:14 EDTBTUPeabody expects to realize improvement in annual cash outlays by early 2017
Subscribe for More Information
08:14 EDTBTUPeabody cuts FY15 sales volumes to 225M-245M tons from 235M-255M tons
Subscribe for More Information
08:11 EDTBTUPeabody expects US costs per ton to improve 3%-5% in 2015
Subscribe for More Information
08:11 EDTBTUPeabody expects 55 GW of US coal-fueled generation to retire by 2017
Subscribe for More Information
08:10 EDTBTUPeabody expects US coal demand to decline 90M-100M tons in 2015
Subscribe for More Information
08:10 EDTBTUPeabody reports Q2 adjusted EPS (65c), consensus (61c)
Subscribe for More Information
08:09 EDTBTUPeabody reports Q2 US Mining adjusted EBITDA $211.5M
Subscribe for More Information
08:09 EDTBTUPeabody Q2 US coal pricing decline, reflecting slower global economic growth
In the second quarter, seaborne and U.S. coal pricing declined, reflecting slower global economic growth, declining steel demand and weak U.S. natural gas prices. In response, U.S. and seaborne supply reductions are occurring, with shipment declines accelerating in several regions. Within U.S. coal markets, coal generation declined 14 percent through June due to lower natural gas prices.
July 27, 2015
11:57 EDTGILDStocks with call strike movement; FB GILD
Subscribe for More Information
08:42 EDTGILDGilead July weekly volatility increases into Q2 and outlook
Subscribe for More Information
05:56 EDTGILDStocks with implied volatility movement; CRM GILD
Subscribe for More Information
July 24, 2015
06:27 EDTGILDGilead price target raised to $131 from $120 at Piper Jaffray
Subscribe for More Information
July 23, 2015
12:45 EDTGILDGilead July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
July 22, 2015
10:01 EDTBTUOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:23 EDTBTUPeabody downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
July 21, 2015
14:12 EDTGILDGilead reports study of E/C/F/TAF met primary endpoint
Gilead Sciences announced detailed 48-week data from an open-label Phase 3 study evaluating its investigational once-daily single tablet regimen of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg, or E/C/F/TAF, among 1,436 virologically suppressed adult patients switching from tenofovir disoproxil fumarate-containing regimens. The study met its primary endpoint by demonstrating non-inferiority of E/C/F/TAF to the TDF-based regimens at Week 48. The study also demonstrated statistical superiority among patients with HIV-1 RNA levels less than 50 copies/mL at Week 48 and statistically significant improvements in bone and renal laboratory parameters. These data were presented in an oral session at the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention in Vancouver, Canada. Among the 1,436 patients who were randomized in the study, virologic success rates at Week 48 were higher in patients taking E/C/F/TAF, 97% versus 93% for all TDF-based regimens; difference in percentages: 4.1%, 95% CI: 1.6% to 6.7%. The rates of virologic failure were similar between the two arms, with E/C/F/TAF, 1.0% and TDF-based regimen, 1.3%. General safety was similar between the two arms through 48 weeks of treatment, with similar percentages of patients in each group having any adverse events. Adverse events leading to treatment discontinuation were more common among patients treated with a TDF-based regimen.
July 20, 2015
07:33 EDTGILDInternational AIDS Society to hold a conference
Subscribe for More Information
06:00 EDTBTUStocks with implied volatility movement; BTU MRVL
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use